Amicus Therapeutics’ fair value estimate has been maintained at US$14.50 per share, with analysts keeping the central price target steady despite several small model tweaks. Much of the current debate ...
BioMarin PharmaceuticalBMRN said Friday it will acquire Amicus TherapeuticsFOLD for $4.8 billion in a deal that adds two rare disease drugs to its portfolio. On the stock market today, Amicus stock ...
Why Amicus Therapeutics stands out today Amicus Therapeutics (FOLD) has drawn attention recently as investors weigh its current share price of US$14.37 against the company’s rare disease portfolio, ...
PRINCETON, N.J., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the presentation of new data from clinical and real-world studies of Galafold ® (migalastat) in ...
By broadening access to curated GLA variant evidence in both Mastermind and ClinVar, enomenon and Amicus aim to support faster, more confident interpretation of genetic tests and reduce delays to ...
Amicus Therapeutics Inc. (NASDAQ:FOLD) is one of the 13 hot stocks to buy with the highest upside potential. On January 27, TD Cowen analyst Ritu Baral maintained the firm’s Hold rating on Amicus ...
Total Revenue of $634M, up 17% Year-over-Year at CER Cash Position of $294M, a $44M Increase in 2025 Proposed Acquisition by BioMarin Expected to Close in Q2 2026, Subject to Closing Conditions ...
Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.06 per share a year ago. These ...
About GalafoldGalafold® (migalastat) 123 mg capsules is an oral pharmacological chaperone of alpha-Galactosidase A (alpha-Gal A) for the treatment of Fabry disease in adults who have amenable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results